The independent financial analyst theScreener just upgraded the general evaluation of MULTIPLAN CORP (US), a company active in the Medical Supplies industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date December 17, 2021, the closing price was USD 4.17 and its...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.